Fundraising FoxDCVC Bio — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)Andrew Scharenberg(Founder)Michael Jensen(Founder)Philip Low(Founder)Ryan Crisman(Founder)
Board seatJohn Hamer· per SEC Form D
Co-investorsMPM BioImpactQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundAlexandria+2 more
CH4 Global develops greenhouse gas mitigation solutions centered on Asparagopsis seaweed, producing feed supplements that reduce enteric methane emissions from cattle for the livestock and agriculture industries.
AgTechCleantechClimate TechFoodTech
Steve Meller(CEO, President & Co-Founder)in
Co-investorsCleveland AvenueDCVC (Data Collective)Nextwave [X] PartnersAgFunder
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Epsilon Holdings, Inc.BioPhero
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.